Literature DB >> 1533289

A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects.

O Kalus1, S Wetzler, R S Kahn, G M Asnis, H M van Praag.   

Abstract

A placebo-controlled dose-response study of the direct serotonin receptor agonist m-chlorophenylpiperazine (MCPP), intravenously infused over 90 s in 0.06 and 0.08 mg/kg doses, was conducted in nine normal male subjects. Cortisol, prolactin, MCPP serum levels and behavioral responses were measured over a 210-min period. Both doses caused significant cortisol and prolactin release and were associated with significantly greater behavioral effects as compared to placebo. Though the two doses were associated with different MCPP serum levels, they did not significantly differ in their hormonal and behavioral effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533289     DOI: 10.1007/bf02245423

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder.

Authors:  R S Kahn; G M Asnis; S Wetzler; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.

Authors:  D S Charney; W K Goodman; L H Price; S W Woods; S A Rasmussen; G R Heninger
Journal:  Arch Gen Psychiatry       Date:  1988-02

3.  Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.

Authors:  E Hollander; M Fay; B Cohen; R Campeas; J M Gorman; M R Liebowitz
Journal:  Am J Psychiatry       Date:  1988-08       Impact factor: 18.112

4.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.

Authors:  R S Kahn; O Kalus; S Wetzler; W Cahn; G M Asnis; H M van Praag
Journal:  Psychiatry Res       Date:  1990-08       Impact factor: 3.222

6.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

7.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

8.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

9.  Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.

Authors:  J Zohar; E A Mueller; T R Insel; R C Zohar-Kadouch; D L Murphy
Journal:  Arch Gen Psychiatry       Date:  1987-11

10.  A diagnostic interview: the schedule for affective disorders and schizophrenia.

Authors:  J Endicott; R L Spitzer
Journal:  Arch Gen Psychiatry       Date:  1978-07
View more
  2 in total

Review 1.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

2.  Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects.

Authors:  R S Kahn; M A Kling; S Wetzler; G M Asnis; H van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.